Medtronic, J&J race toward artificial pancreas

Medtronic is seeking FDA approval for its combination Paradigm Veo device.--Courtesy of Medtronic

Despite all the advances in medical devices for Type 1 diabetes, nothing resembling an artificial pancreas has made its way to the market stateside, but companies like Medtronic ($MDT), Johnson & Johnson ($JNJ) and Tandem are working to push the technology forward.

As The Wall Street Journal reports, Medtronic is going through the FDA process with Paradigm Veo, a closed-loop insulin pump that can detect blood glucose content and suspend delivery when it veers from healthy levels, slashing rates of hypoglycemia. Meanwhile, Animas, J&J's diabetes unit, is co-developing a combination insulin pump-blood glucose monitor with Dexcom ($DXCM), also seeking FDA approval.

And while those devices promise to ease the lives of U.S. diabetics, the gold standard remains a full-fledged artificial pancreas: an implanted device that can continuously monitor blood sugar and mete out insulin as needed.

Johnson & Johnson is conducting a second feasibility study on its artificial pancreas.--Courtesy of J&J

Animas leads the way on that front, working through a second feasibility study of its external device, but Tandem and Medtronic have partnered with the Juvenile Diabetes Research Foundation to advance their technologies toward realizing a fully automated monitor/pump combo.

Along the way, each company is vying for dominance in the swelling diabetes market, and whoever can first commercialize a major advance in the convenience of treatment for the country's more than 1 million patients with Type 1 diabetes will likely reap a hefty windfall.

"The end of the rainbow is some automated device that will be able to come close to normalizing glucose," Medtronic Diabetes CMO Francine Kaufman told the WSJ.

- read the WSJ story

Editor's note: An earlier version of this story misstated how Paradigm Veo operates. We regret the error.

Suggested Articles

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.